Paolo Ghia, MD, PhD, on the Chemo-Free, All-Oral Regimen of Ibrutinib Plus Venetoclax for First-Line CLL at ASCO 2021

News
Video

Paolo Ghia, MD, PhD, discussed data from the CAPTIVATE trial of ibrutinib/venetoclax in the frontline setting for chronic lymphocytic leukemia.

CancerNetwork® sat down with Paolo Ghia, MD, from the Universita Università Vita-Salute San Raffaele, at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting to talk about the CAPTIVATE trial (NCT02910583) examining the chemotherapy-free regimen of ibrutinib (Imbruvica) and venetoclax (Venclexta) for patients with chronic lymphocytic leukemia (CLL). With the all-oral therapy regimen, patients experienced promising progression-free survival and overall survival.

Transcript:

This [regimen] is really opening a new way of treating patients with chronic lymphocytic leukemia, because so far we are used to continuing treatment, which [has] revolutionized the treatment in CLL. With the advent of oral therapies, [patients] indeed experienced increases in the progression-free survival and overall survival. Of course, having a fixed-duration treatment might be very beneficial for our patient because that would allow [us] to stop the treatment after a number of months, preventing the long-term adverse events, but also the possibility of the occurrence gene mutations and therefore resistance to the drugs.

Reference

Ghia P, Allan J, Siddiqi T et al. Fixed-duration (FD) first-line treatment (tx) with ibrutinib (I) plus venetoclax (V) for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of the FD cohort of the phase 2 captivate study. J Clin Oncol. 39;2021(suppl 15):7501. doi: 10.1200/JCO.2021.39.15_suppl.7501

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Related Content